Proof-of-concept study for Imunon's first vaccine utilizing its proprietary PlaCCine platform is now open for enrollment Topline results expected this year LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced that DM Clinical Research in Philadelphia is the first site activated and ready for patient recruitment for its Phase 1 study w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-15911 Imunon, Inc. (Exact name of Registrant as specified in its charter) Delaware 52-1256615 (State ...

Exhibit 99.1 IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update "Potential key value-creating milestones are upon us. We expect that this summer will be rewarding and busy as we look to improve the treatment paradigm in late-stage ovarian cancer and to offer an "mRNA-better" vaccine platform technology with excellent commercial promise," said Mr. Michael H. Tardugno, IMUNON's Executive Chairman. Dr. Lindborg, a globally recognized biostatistician, has nearly 30 years of pharmac ...

Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experience in drug development and business strategy LAWRENCEVILLE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced the appointment of Stacy R. Lindborg, Ph.D. as President and Chief Executive Officer, effective May 13, 2024. Dr ...

LAWRENCEVILLE, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Monday, May 13, 2024 to discuss financial results for the first quarter ended March 31, 2024 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinica ...

Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in the second quarter LAWRENCEVILLE, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces receipt of clearance from the U.S. Food and Drug Administration (FDA) to begin a Phase 1 clinical trial with a seasonal COVID-19 booster vaccine. The company filed ...

LAWRENCEVILLE, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN) ("IMUNON" or the "Company"), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today announced that on April 10, 2024, it received written notice from the staff of The NASDAQ Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Minimum ...

Imunon, Inc. (NASDAQ:IMNN) Q4 2023 Earnings Conference Call March 28, 2024 10:00 AM ET Company Participants Kim Golodetz - Investor Relations, LHA Michael Tardugno - Executive Chairman Sebastien Hazard - Executive Vice President and Chief Medical Officer Kursheed Anwer - Executive Vice President and Chief Science Officer Jeffrey Church - Chief Financial Officer Conference Call Participants Laura Suriel - Alliance Global Partners David Bautz - Zacks Small-Cap Research Kemp Dolliver - Brookline Capital Market ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ COMMISSION FILE NO.: 001-15911 IMUNON, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE 52-1256615 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. (State or other jurisdic ...

Financial Performance - IMUNON reported a net loss of $19.5 million for 2023, a decrease from a net loss of $35.9 million in 2022, equating to $2.16 per share compared to $5.03 per share in the previous year[18]. - Total operating expenses for 2023 were $21.0 million, down from $25.4 million in 2022, reflecting a 17.3% reduction[31]. - Cash used for operating activities decreased to $19.0 million in 2023 from $23.1 million in 2022, primarily due to a one-time interest expense of $4.5 million in 2022[22]. - The Company ended 2023 with $15.7 million in cash, investments, and accrued interest receivable, which is expected to fund operations into Q4 2024[23]. - The Company has no licensing revenue in 2023, compared to $500,000 in 2022[31]. - Total assets decreased to $21.9 million in 2023 from $44.0 million in 2022, a decline of 50.2%[33]. Operating Expenses - Operating expenses for 2023 were $21.0 million, down by $4.4 million or 17% from $25.4 million in 2022[18]. - General and administrative expenses decreased to $9.7 million in 2023 from $13.7 million in 2022, primarily due to lower non-cash stock compensation and employee-related costs[20]. - General and administrative expenses decreased to $9.7 million in 2023 from $13.7 million in 2022, a reduction of 29.0%[31]. - CMC costs increased to $2.3 million in 2023 from $1.2 million in 2022 due to the development of in-house pilot manufacturing capabilities[19]. Research and Development - Research and development (R&D) expenses were $11.3 million for 2023, a slight decrease from $11.7 million in 2022, with costs associated with the OVATION 2 Study at $1.2 million[19]. - The Company is advancing its lead clinical program, IMNN-001, for advanced ovarian cancer, currently in Phase 2 development[27]. - The Phase 1/2 clinical trial evaluating IMNN-001 in combination with bevacizumab has enrolled four patients, with a total of 50 patients expected to be enrolled[10][11]. - Interim data from the OVATION 2 Study indicated a 30% delay in disease progression or death in the treatment arm compared to the control arm, with an approximate nine-month improvement in overall survival[2]. - IMUNON submitted an Investigational New Drug (IND) application for a Phase 1/2 clinical trial of a seasonal COVID-19 booster vaccine in Q1 2024[2]. - The Company is entering a first-in-human study of its COVID-19 booster vaccine, IMNN-101[27]. - The PlaCCine modality demonstrated robust and durable T cell responses in preclinical studies, outperforming commercial mRNA vaccines in animal models[4].